STOCK TITAN

Alnylam Pharmaceuticals Inc - ALNY STOCK NEWS

Welcome to our dedicated news page for Alnylam Pharmaceuticals (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alnylam Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alnylam Pharmaceuticals's position in the market.

Rhea-AI Summary
FDA issues Complete Response Letter to Alnylam Pharmaceuticals regarding patisiran for the treatment of cardiomyopathy of ATTR amyloidosis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals to present new results for patisiran at the Heart Failure Society of America Annual Scientific Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences clinical trial
-
Rhea-AI Summary
Alnylam Pharmaceuticals' patisiran receives positive outcome from FDA advisory committee meeting for treatment of ATTR amyloidosis cardiomyopathy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.78%
Tags
none
Rhea-AI Summary
NASDAQ halts trading of Alnylam Pharmaceuticals (ALNY) as FDA reviews supplemental New Drug Application for patisiran, an RNAi therapeutic for cardiomyopathy of ATTR amyloidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals announces positive results for zilebesiran in the treatment of hypertension
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
none
Rhea-AI Summary
Alnylam Pharmaceuticals provides an update on ongoing patent infringement litigation against Moderna and Pfizer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) reports 43% YoY growth in Q2 2023 global net product revenues, submits APOLLO-B data to FDA for Patisiran, and enters into strategic collaboration with Roche for Zilebesiran.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
earnings
-
Rhea-AI Summary
ALNY - Alnylam Pharmaceuticals to Present Company Overview at Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
Rhea-AI Summary
Alnylam Pharmaceuticals has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Alnylam will receive an upfront cash payment of $310 million and is eligible for additional milestone payments, bringing the potential deal value up to $2.8 billion. Alnylam and Roche will co-commercialize zilebesiran in the U.S., while Roche obtains exclusive rights to commercialize it outside the U.S. Zilebesiran has shown promising results in Phase 1 studies, demonstrating consistent and durable blood pressure reduction. The partnership aims to disrupt the hypertension treatment paradigm globally and advance Alnylam's P5x25 strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
partnership
Alnylam Pharmaceuticals Inc

Nasdaq:ALNY

ALNY Rankings

ALNY Stock Data

18.82B
125.42M
0.4%
95.08%
2.13%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About ALNY

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.